Trefoil factor-1 upregulation in estrogen-receptor positive breast cancer correlates with an increased risk of bone metastasis

Bone ◽  
2021 ◽  
Vol 144 ◽  
pp. 115775
Author(s):  
Chiara Spadazzi ◽  
Laura Mercatali ◽  
Mark Esposito ◽  
Yong Wei ◽  
Chiara Liverani ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Bone Metastasis ◽  
Trefoil Factor ◽  
Increased Risk ◽  
Estrogen Receptor Positive ◽  
Trefoil Factor 1 ◽  
Positive Breast Cancer

scholarly journals Long-Term Sleep Duration as a Risk Factor for Breast Cancer: Evidence from a Systematic Review and Dose-Response Meta-Analysis

2017 ◽  
Vol 2017 ◽  
pp. 1-11 ◽  
Author(s):  
Chunyang Lu ◽  
Hao Sun ◽  
Jinyu Huang ◽  
Songcheng Yin ◽  
Wenbin Hou ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Sleep Duration ◽  
Dose Response ◽  
Nonlinear Relationship ◽  
Increased Risk ◽  
Non Linear ◽  
Estrogen Receptor Positive ◽  
Estrogen Receptor Negative ◽  
Positive Breast Cancer

Sleep patterns have been associated with the development of cancers, although the association between sleep duration and breast cancer remains controversial. The purpose of our study was to explore the relationship between sleep duration and breast cancer risk. The PubMed and Web of Science databases were searched, and restricted cubic splines were used to explore the dose-response relationship. Data from 415,865 participants were derived from 10 studies. A J-shaped nonlinear trend was found between sleep duration and breast cancer incidence (Pnon-linear = 0.012); compared with the reference hours (6 h or 7 h), with increasing sleep hours, the risk of breast cancer increased (Ptrend = 0.028). Moreover, a nonlinear relationship was found between sleep duration and estrogen receptor-positive breast cancer (Pnon-linear = 0.013); the risk of estrogen receptor-positive breast cancer increased with increasing sleep hours compared to the reference hours (Ptrend = 0.024). However, no nonlinear relationship was found between sleep duration and estrogen receptor-negative breast cancer; the risk of estrogen receptor-negative breast cancer was 1.035 for every additional sleep hour. Compared to women with the reference number of sleep hours, women with a longer sleep duration might have a significantly increased risk of breast cancer, especially estrogen receptor-positive breast cancer.

scholarly journals CHEK2*1100delC Heterozygosity in Women With Breast Cancer Associated With Early Death, Breast Cancer–Specific Death, and Increased Risk of a Second Breast Cancer

2012 ◽  
Vol 30 (35) ◽  
pp. 4308-4316 ◽  
Author(s):  
Maren Weischer ◽  
Børge G. Nordestgaard ◽  
Paul Pharoah ◽  
Manjeet K. Bolla ◽  
Heli Nevanlinna ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
White Women ◽  
Estrogen Receptor Status ◽  
Early Death ◽  
Chek2 1100Delc ◽  
Increased Risk ◽  
Estrogen Receptor Positive ◽  
Second Breast Cancer ◽  
Positive Breast Cancer

Purpose We tested the hypotheses that CHEK2*1100delC heterozygosity is associated with increased risk of early death, breast cancer–specific death, and risk of a second breast cancer in women with a first breast cancer. Patients and Methods From 22 studies participating in the Breast Cancer Association Consortium, 25,571 white women with invasive breast cancer were genotyped for CHEK2*1100delC and observed for up to 20 years (median, 6.6 years). We examined risk of early death and breast cancer–specific death by estrogen receptor status and risk of a second breast cancer after a first breast cancer in prospective studies. Results CHEK2*1100delC heterozygosity was found in 459 patients (1.8%). In women with estrogen receptor–positive breast cancer, multifactorially adjusted hazard ratios for heterozygotes versus noncarriers were 1.43 (95% CI, 1.12 to 1.82; log-rank P = .004) for early death and 1.63 (95% CI, 1.24 to 2.15; log-rank P < .001) for breast cancer–specific death. In all women, hazard ratio for a second breast cancer was 2.77 (95% CI, 2.00 to 3.83; log-rank P < .001) increasing to 3.52 (95% CI, 2.35 to 5.27; log-rank P < .001) in women with estrogen receptor–positive first breast cancer only. Conclusion Among women with estrogen receptor–positive breast cancer, CHEK2*1100delC heterozygosity was associated with a 1.4-fold risk of early death, a 1.6-fold risk of breast cancer–specific death, and a 3.5-fold risk of a second breast cancer. This is one of the few examples of a genetic factor that influences long-term prognosis being documented in an extensive series of women with breast cancer.

scholarly journals Serum Estradiol and 20 Site-Specific Cancers in Women: Mendelian Randomization Study

2021 ◽  
Author(s):  
Susanna C Larsson ◽  
Siddhartha Kar ◽  
John R B Perry ◽  
Paul Carter ◽  
Mathew Vithayathil ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ovarian Cancer ◽  
Estrogen Receptor ◽  
Endometrial Cancer ◽  
Mendelian Randomization ◽  
Site Specific ◽  
Increased Risk ◽  
Estrogen Receptor Positive ◽  
Positive Breast Cancer

Abstract Context The causal role of endogenous estradiol in cancers other than breast and endometrial cancer remains unclear. Objective To assess the causal associations of endogenous 17β-estradiol (E2), the most potent estrogen, with cancer risk in women through Mendelian randomization. Methods As primary genetic instrument, we used a genetic variant in the CYP19A1 gene that is strongly associated with serum E2 levels. Summary statistics genetic data for the association of the E2 variant with breast, endometrial, and ovarian cancer were obtained from large-scale consortia. We additionally estimated the associations of the E2 variant with any and 20 site-specific cancers in 198 825 women of European descent in UK Biobank. Odds ratios (OR) of cancer per 0.01 unit increase in log-transformed serum E2 levels in pmol/L were estimated using the Wald ratio. Results Genetic predisposition to higher serum E2 levels was associated with increased risk of estrogen receptor positive breast cancer (OR 1.02; 95% confidence interval [CI] 1.01-1.03; P=2.5×10 -3), endometrial cancer overall (OR 1.09; 95% CI 1.06-1.11; P=7.3×10 -13), and endometrial cancer of the endometrioid histology subtype (OR 1.10; 95% CI 1.07-1.13; P=2.1×10 -11). There were suggestive associations with breast cancer overall (OR 1.01; 95% CI 1.00-1.02; P=0.02), ovarian cancer of the endometrioid subtype (OR 1.05; 95% CI 1.01-1.10; P=0.02), and stomach cancer (OR 1.12; 95% CI 1.00-1.26; P=0.05), but no significant association with other cancers. Conclusion This study supports a role of E2 in the development of estrogen receptor positive breast cancer and endometrioid endometrial cancer, but found no strong association with other cancers in women.

Sign in / Sign up

Export Citation Format

Share Document